Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Lifted by Clean Yield Group

Clean Yield Group increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 18.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,646 shares of the medical equipment provider’s stock after acquiring an additional 7,266 shares during the quarter. Clean Yield Group’s holdings in Hologic were worth $3,291,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Wolff Wiese Magana LLC acquired a new position in shares of Hologic in the third quarter worth about $25,000. General Partner Inc. acquired a new position in Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment raised its stake in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Sunbelt Securities Inc. acquired a new stake in Hologic during the 2nd quarter valued at $37,000. Finally, First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $0.73 during mid-day trading on Monday, hitting $70.97. The company had a trading volume of 1,991,492 shares, compared to its average volume of 1,970,938. Hologic, Inc. has a 12 month low of $69.46 and a 12 month high of $84.67. The firm has a market cap of $16.11 billion, a P/E ratio of 21.31, a PEG ratio of 2.32 and a beta of 0.97. The business’s 50-day simple moving average is $75.88 and its 200-day simple moving average is $78.55. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the company earned $0.89 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on HOLX shares. UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Morgan Stanley lowered their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday. Finally, Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.